Latest News and Updates

* (R) = Regulatory press releases

May 23, 2023

(R) Annual General Meeting in Cantargia AB (publ)

May 23, 2023

(R) Cantargia publishes interim report for the first quarter of 2023

May 15, 2023

(R) Cantargia intensifies development of nadunolimab in pancreatic cancer with new controlled phase IIb clinical trial following strong phase IIa efficacy results

May 9, 2023

Invitation to presentation of Cantargia’s report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST

Apr 27, 2023

(R) Cantargia publishes annual report for the financial year 2022

Apr 24, 2023

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 21, 2023

(R) Cantargia reports favorable safety of new nadunolimab combination therapy and completes enrollment in non-small cell lung cancer trial

Apr 20, 2023

(R) Cantargia has submitted a phase I clinical trial application for its second project, CAN10

Apr 19, 2023

(R) Cantargia presents anti-metastatic effects of nadunolimab in cancer models at AACR 2023

Apr 17, 2023

(R) Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Annual General Meeting in Cantargia AB (publ)

(R) Cantargia publishes interim report for the first quarter of 2023

(R) Cantargia intensifies development of nadunolimab in pancreatic cancer with new controlled phase IIb clinical trial following strong phase IIa efficacy results

Invitation to presentation of Cantargia’s report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST

(R) Cantargia publishes annual report for the financial year 2022

(R) Notice of annual general meeting in Cantargia AB (publ)

(R) Cantargia reports favorable safety of new nadunolimab combination therapy and completes enrollment in non-small cell lung cancer trial

(R) Cantargia has submitted a phase I clinical trial application for its second project, CAN10

(R) Cantargia presents anti-metastatic effects of nadunolimab in cancer models at AACR 2023

(R) Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07